在重症监护病人的严重急性心力衰竭中,MAPK,PI3K/Akt路径和GSK-3β活性:更新的审查
Massimo Meco1, Enrico Giustiniano2, Fulvio Nisi2
1Anesthesia and Intensive Care Department, San Carlo Clinic, Paderno Dugnano, 20030 Milan, Italy.
Journal of cardiovascular development and disease
|July 25, 2025
概括
本综述探讨了急性心力衰竭 (AHF) 中的MAPK,PI3K/Akt和GSK-3β等信号通路. 了解这些途径为AHF机制和潜在的治疗点提供了洞察力,以获得更好的心脏结果.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 生物化学 生物化学
背景情况:
- 急性心力衰竭 (AHF) 涉及到心力衰竭症状的快速恶化,通常由心肌缺血或损伤引发.
- 细胞内信号传导级联,包括基因激活蛋白激酶 (MAPK) 途径,是AHF病理生理学的核心.
- 这些通路调解关键的细胞反应,如炎症,亡和心脏重塑.
研究的目的:
- 审查最近在了解MAPK,PI3K/Akt和糖原合成酶激酶-3β (GSK-3β) 在AHF中的信号传导方面的进展.
- 强调机械学的见解,临床前模型和新兴的治疗目标.
- 突出PI3K/Akt和GSK-3β在AHF中的双重作用,作为补偿标记物和治疗点.
主要方法:
- 审查最近的科学文献和临床前研究.
- 对参与急性心脏应激和损伤的信号通路的分析.
- 专注于对MAPK,PI3K/Akt和GSK-3β活动的机制性见解.
主要成果:
- MAPK通路 (ERK1/2,p38,JNK) 被像Ang II和ET-1这样的刺激激活,导致炎症和重塑.
- PI3K/Akt信号传递起着双重作用,通过抗亡作用提供心脏保护,但在持续激活的情况下可能导致功能障碍.
- GSK-3β被确定为细胞亡,炎症和心脏重塑的关键调节者,越来越多的证据表明它在急性心肌压力中的作用.
结论:
- MAPK,PI3K/Akt和GSK-3β通路的调节失调与AHF有关.
- 这些途径代表了治疗急性心脏事件管理的有希望的治疗点.
- 对这些信号级联的进一步研究可以导致新的AHF治疗方法.
关键词:
这是GSK-3ββ.在MAPK信号传输中.通过PI3K/Akt路径.急性心力衰竭是什么意思进行心脏重塑.心肌细胞亡 (cardiomyocyte apoptosis) 是一种导致心肌细胞亡的过程.更多相关视频
08:00Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
Published on: July 10, 2019
6.2K
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
8.6K
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
MAPK Signaling Cascades
6.1K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.1K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
510
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510
Heart Failure II: Pathophysiology
44
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
44
